BACKGROUND: Esophagectomy with three-field lymphadenectomy has been performed for esophageal cancer. Detailed analysis of cause of death and mode of recurrence is required to determine the need for further adjuvant therapy and follow-up. MATERIALS AND METHODS: A total of 208 patients who underwent esophagectomy through right thoracotomy with three-field lymphadenectomy were enrolled into the present study. Mode of first recurrence was divided into four groups: lymph node, hematogenous, mixed, and local recurrence. RESULTS: Excluding 16 hospital deaths, the number of deaths and 5-year survival rates were 104 patients and 7.8% for cancer recurrence, 12 patients and 53.8% for second primary cancers in other organs, and 34 patients and 31.0% for causes of death unrelated to carcinoma. In the 104 patients with relapse, 5-year survival rate of patients was 14.3% with lymph node recurrence (n = 29), 9.1% with hematogenous recurrence (n = 32), 3.1% with mixed recurrence (n = 35), and 12.5% with local recurrence (n = 8). CONCLUSION: To improve outcomes for esophagectomy with three-field lymphadenectomy, early detection of recurrent disease and regular examination of the entire body for secondary cancer is necessary.
BACKGROUND: Esophagectomy with three-field lymphadenectomy has been performed for esophageal cancer. Detailed analysis of cause of death and mode of recurrence is required to determine the need for further adjuvant therapy and follow-up. MATERIALS AND METHODS: A total of 208 patients who underwent esophagectomy through right thoracotomy with three-field lymphadenectomy were enrolled into the present study. Mode of first recurrence was divided into four groups: lymph node, hematogenous, mixed, and local recurrence. RESULTS: Excluding 16 hospital deaths, the number of deaths and 5-year survival rates were 104 patients and 7.8% for cancer recurrence, 12 patients and 53.8% for second primary cancers in other organs, and 34 patients and 31.0% for causes of death unrelated to carcinoma. In the 104 patients with relapse, 5-year survival rate of patients was 14.3% with lymph node recurrence (n = 29), 9.1% with hematogenous recurrence (n = 32), 3.1% with mixed recurrence (n = 35), and 12.5% with local recurrence (n = 8). CONCLUSION: To improve outcomes for esophagectomy with three-field lymphadenectomy, early detection of recurrent disease and regular examination of the entire body for secondary cancer is necessary.
Authors: S Kinugasa; M Tachibana; H Yoshimura; D K Dhar; M Shibakita; S Ohno; H Kubota; R Masunaga; N Nagasue Journal: Ann Thorac Surg Date: 2001-02 Impact factor: 4.330
Authors: S Natsugoe; H Okumura; M Matsumoto; Y Uchikado; T Setoyama; Y Uenosono; S Ishigami; T Owaki; T Aikou Journal: Eur J Surg Oncol Date: 2006-03-29 Impact factor: 4.424
Authors: H Shiozaki; M Yano; T Tsujinaka; M Inoue; S Tamura; Y Doki; T Yasuda; Y Fujiwara; M Monden Journal: Dis Esophagus Date: 2001 Impact factor: 3.429
Authors: T Lerut; P Nafteux; J Moons; W Coosemans; G Decker; P De Leyn; D Van Raemdonck; N Ectors Journal: Ann Surg Date: 2004-12 Impact factor: 12.969
Authors: S Natsugoe; J Mueller; F Kijima; K Aridome; M Shimada; K Shirao; C Kusano; M Baba; H Yoshinaka; T Fukumoto; T Aikou Journal: Br J Cancer Date: 1997 Impact factor: 7.640